Starton Holdings, Inc.

S-1/A amended

Range $5.00 to $7.00 · 5,000,000 shares

S-1/A amended

Range $5.00 to $7.00 · 6,666,667 shares · Gross proceeds $46,666,669

S-1/A amended

Price $6.00 · Range $5.00 to $7.00 · 6,666,667 shares

Starton Holdings, Inc. is conducting an initial public offering (IPO) of 6,666,667 shares of common stock, with an estimated price range of $5.00 to $7.00 per share. The company, a clinical-stage biotechnology firm, focuses on developing continuous delivery systems for cancer therapies using its proprietary platform. Its lead program, STAR-LLD, involves low-dose lenalidomide formulations for hematologic malignancies, while another candidate, STAR-OLZ, targets chemotherapy-induced nausea but is currently on hold. The IPO aims to fund clinical trials and expand its pipeline, with shares expected to list on Nasdaq under the symbol 'STA'.

S-1/A amended

Range $5.00 to $7.00 · 6,666,667 shares

Starton Holdings, Inc. is conducting an IPO for 6,666,667 shares of common stock at an estimated price range of $5.00 to $7.00 per share. The company, a clinical-stage biotechnology firm, focuses on developing cancer therapies using proprietary delivery technologies. The S-1/A amendment reflects updates to the offering timeline, including the expected share delivery date in 2026 and structural changes such as a reorganization section. The filing emphasizes risks related to clinical trial outcomes, regulatory approvals, and reliance on key programs like STAR-LLD and STAR-OLZ.

S-1 filed

Range $5.00 to $7.00 · 6,666,667 shares

Starton Holdings, Inc. is a clinical-stage biotechnology company focused on developing cancer therapies using proprietary delivery technologies. The company is conducting an initial public offering (IPO) of 6,666,667 shares of common stock, with an estimated price range of $5.00 to $7.00 per share. The offering aims to fund continued development of its lead program, STAR-LLD, a continuous delivery system for lenalidomide, and other pipeline candidates. Starton is an emerging growth company and smaller reporting company, which affects its regulatory reporting requirements.

DRS/A amended

Starton Holdings, Inc. highlights ongoing challenges in securing sufficient financing, developing and commercializing new pharmaceutical products, and navigating regulatory approvals. The company emphasizes risks related to reliance on third-party suppliers, competition, and the uncertainty of research and development outcomes. Continued losses and dependence on external capital are recurring themes, with no significant shifts from the previous filing.

DRS filed

Starton Holdings, Inc. is seeking additional financing to support its operations and product development, given its history of operating losses and reliance on research and development. The company faces significant risks in product commercialization, including regulatory delays, competition, supply chain vulnerabilities, and the inability to secure sufficient capital. Its future profitability depends on successful FDA approvals, timely product launches, and managing development costs, with no assurance of long-term financial viability.